To compare alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins in the ODYSSEY DM-DYSLIPIDEMIA trial (NCT02642159). Results: The randomized population comprised 413 individuals (intention-to-treat population, n = 409; safety population, n = 412). At week 24, the mean non-HDL cholesterol reductions were superior with alirocumab (−32.5% difference vs UC, 97.5% confidence interval −38.1 to −27.0; P < .0001). Overall, 63.6% of alirocumab-treated individuals were maintained on 75 mg every 2 weeks. Alirocumab also reduced LDL cholesterol (−43.0%), apolipoprotein B (−32.3%), total cholesterol (−24.6%) and LDL particle number (−37.8%) at week 24 vs UC (all P < .0001).
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| INTRODUCTION
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality among individuals with type 2 diabetes mellitus (T2DM). 1 The reasons are probably multifactorial, but a relevant contributory factor may be the greater prevalence of mixed dyslipidaemia, which is characterized by elevated triglyceride (TG) levels and thus elevated TG-rich lipoprotein (TRL) and TRL cholesterol levels, as well as low levels of HDL cholesterol. 2 Mixed dyslipidaemia in T2DM
might not be detected with measurement of LDL cholesterol levels, as these may remain within a normal range. with a higher number of smaller, more dense LDL particles; these are believed to be more atherogenic than larger, more buoyant particles. 2 Lipid-lowering therapy (LLT) with statins increases the clearance of atherogenic lipoproteins and thus reduces plasma cholesterol levels, principally through reductions in LDL cholesterol. 6 This results in a significantly lower risk of ASCVD with the proportional benefit related to the absolute reduction in LDL cholesterol. 7 Other therapeutic approaches that further increase clearance of atherogenic lipoproteins include ezetimibe 8 and the inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9), alirocumab 9 and evolocumab. 10 Adding ezetimibe or evolocumab to statin significantly reduces CV events (the CV outcomes study with alirocumab
[NCT01663402] is ongoing) 11, 12 ; however, no previous study has prospectively evaluated PCSK9 inhibition in individuals with diabetes and mixed dyslipidaemia or compared different therapeutic options among individuals with elevated TG levels despite maximally tolerated statin therapy, an important consideration given the "realworld" clinical uncertainty around potential therapeutic agents which principally reduce either the synthesis of TRL particles (fibrates), lipolysis of TGs (omega-3 fatty acids), clearance of atherogenic lipoproteins (ezetimibe), or a combination of these mechanisms (nicotinic acid).
The ODYSSEY DM-DYSLIPIDEMIA trial was designed to address these clinical uncertainties and assessed the efficacy and safety of alirocumab vs usual lipid-lowering care (UC), stratified by an investi- The trial protocol was approved by the relevant institutional review boards or independent ethics committees, and all participating individuals provided written informed consent.
| Trial participants
The trial included individuals (aged ≥18 years) with T2DM and mixed dyslipidaemia whose non-HDL cholesterol was not adequately controlled 
| Endpoints and assessments
The primary efficacy endpoint was the percentage change in non-HDL cholesterol from baseline to week 24, analysed using an intention-to-treat approach. Further details on secondary endpoints and laboratory and safety assessments are given in Appendix S1.
| Statistical analysis
The primary efficacy endpoint was analysed using a mixed-effect model with a repeated measures approach to account for missing data. Further information on analysis methods is presented in Appendix S1.
3 | RESULTS
| Participating individuals
Eligible individuals were allocated to UC options by the investigator prior to randomization, and were subsequently randomized within each stratum to either alirocumab or UC option in a 2:1 ratio (Figure 1 ). A total of 413 individuals were randomized to alirocumab (n = 276) or UC (n = 137). The median daily doses of UC treatments are given in Table S1 .
Baseline characteristics and lipid variables were generally similar regardless of treatment allocation (Tables 1 and S2 f Order based on hierarchical order, except for LDL particle size.
g β-quantification.
| Lipid variables
The least-squares mean (SE) percentage change from baseline to week 24 in non-HDL cholesterol was −37.3 (3.0)% with alirocumab and −4.7 (3.3)% with UC (−32.5% difference vs UC, 97.5% confidence interval
[CI] -38.1 to −27.0; P < .0001 [ Figure 2A] ). Alirocumab also significantly lowered levels of measured LDL cholesterol, apolipoprotein (Apo)B, total cholesterol and Lp(a) vs UC (all P < .0001; Figure 2A ). Non-HDL cholesterol and measured LDL cholesterol reductions were observed from the first measured time point at week 8 and maintained through the 24-week treatment period ( Figure S1 ). TG levels were decreased in both arms at week 24, with no significant difference between alirocumab (−13.0%) vs UC (−8.8%; Figure 2A ). As a result of the hierarchical testing procedure used, P values from subsequent testing of secondary endpoints are nominal only. At week 24, alirocumab treatment resulted in improvements from baseline (nominal P value <.025 vs UC) in HDL cholesterol, and LDL particle number and size (Figure 2A ). Results for FIGURE 2 Primary and selected key secondary efficacy endpoints at week 24 for A, the overall study population; B, fenofibrate; C, ezetimibe; D, omega-3 fatty acids and E, no lipid-lowering therapy (ITT analysis). Abbreviations: Apo, apolipoprotein; FA, fatty acids; HDL-C, HDL cholesterol; ITT, intenttion-to-treat; LDL-C, LDL cholesterol; LDL-P, LDL particle; LLT, lipid-lowering therapy; Lp(a), lipoprotein (a); LS, least-squares; TC, total cholesterol; TG, triglyceride. a Statistically significant according to the fixed hierarchical approach used to ensure a strong control of the overall type I error rate at the 0.025 level. ITT analysis includes individuals according to planned treatment (see footnote to Figure 1 ) fenofibrate stratum and other individual UC strata were similar to the overall analysis ( Figure 2B-E) ; as a result of small patient numbers, data
were not analysed for the nicotinic acid stratum. Similar results to those at week 24 were seen at week 12, when all individuals in the alirocumab arm were receiving the 75-mg dose ( Figure S2 ). In the alirocumab group, the dose of 75 mg every 2 weeks was maintained in 63.6% of individuals after week 12.
At week 24, more than two-thirds of alirocumab-treated individuals achieved levels of non-HDL cholesterol <2.59 mmol/L (<100 mg/dL), measured LDL cholesterol <1.81 mmol/L (<70 mg/dL) and ApoB <80 mg/dL (<0.8 g/L; Figure 3 ). In addition, a greater proportion of individuals in the alirocumab group vs UC achieved a reduction in LDL cholesterol from baseline of ≥50% (55.2% vs 3.8%).
Results were consistent across the various subgroups analysed ( Figure S3 ).
| Free and total PCSK9
In the alirocumab group, free PCSK9 levels changed by −43.3% and −60.6% at week 12 and week 24, respectively (UC: +18.2% and +11.8%, respectively; Figure 4 ). Total PCSK9 levels changed by +357.6% at week 12 and +413.3% at week 24 in the alirocumab group (UC: +13.9% and +10.8%, respectively; Figure 4 ). Corresponding data within individual UC strata are also shown in Figure 4 .
| Diabetes-related endpoints
The mean HbA1c and fasting plasma glucose (FPG) levels observed during the study are shown in Figure S4 . 
| Safety
The percentage of individuals who experienced any treatmentemergent adverse events (TEAEs), treatment-emergent serious adverse events and TEAEs leading to discontinuation was similar in the alirocumab and UC groups (Table S4 ).
The TEAEs occurring in ≥2% of individuals were reported at generally similar frequencies in the alirocumab and UC groups, with some TEAEs occurring at higher frequency in the alirocumab vs UC group and vice versa; urinary tract infection (alirocumab: 5.8%; UC: 3.6%) and diarrhoea (alirocumab: 5.1%; UC: 6.6%) were the most common TEAEs (Table S5 ).
In total, 3.0% (n = 8) of individuals receiving alirocumab and 0.8% (n = 1) of those receiving UC had low-titre persistent anti-drug anti- The present study also offers novel insights into the potential mechanisms behind changes in different lipid variables when other LLTs are added to statins and the potential impact of these differential changes on the putative likelihood of future ASCVD. In the overall UC group, mean total and free PCSK9 concentrations changed by +10.8% and +11.8%, respectively, at week 24 compared with baseline; larger increases were seen in the fenofibrate group and also (to a lesser extent) in the ezetimibe group, in line with previous observations that treatment with these LLTs increases PCSK9 levels. 14, 15 Omega-3 fatty acids appeared to have a negligible effect on PCSK9 levels. The increases in PCSK9 levels in the overall UC group were associated with only modest reductions from baseline to week 24 in ApoB (−1.6%) and LDL particle number (−3.9%), and increase in LDL particle size (+0.3%) and therefore modest reductions Whilst the present data cannot be used to assess whether favourable changes in atherogenic particle clearance will translate into better clinical outcomes in patients with T2DM and atherogenic dyslipidaemia, it should be noted that UC failed to achieve non-HDL cholesterol levels <2.59 mmol/L (<100 mg/dL; recommended as a treatment target for individuals with T2DM in guidelines 4, 5 ) for the majority (82.3%). In contrast, at week 24, only 33.1% of the alirocumab group failed to achieve non-HDL cholesterol levels <2.59 mmol/L (<100 mg/dL). The findings were consistent with previous subgroup or post hoc analyses which have reported the effect of PCSK9 inhibitors according to mixed dyslipidaemia or diabetes status.
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This study was not designed to assess CV outcomes. Non-HDL cholesterol was chosen as the primary endpoint in this study after reports that it represents a better risk marker than LDL cholesterol when TG levels are elevated 4 ; however, we acknowledge that there is no direct strong evidence from randomized trials that additional changes in non-HDL cholesterol, on top of LDL cholesterol reductions, contribute to further CVD reduction. Moreover, it is difficult to separate reductions in non-HDL cholesterol, LDL cholesterol, ApoB and LDL particle number, which are highly correlated. There are data from meta-analyses suggesting that greater reductions in non-HDL cholesterol and ApoB are related to further reductions in CVD, 28, 29 analogous to well-established data for LDL cholesterol reduction. 7, 12, 26 The importance of reducing atherogenic particle number has gained further credence with the large genetic analyses by Ference et al 30 demonstrating that, with add-on therapy, which affects both the quality and content of atherogenic particles, any CV benefit is more accurately predicted by particle number (as depicted by changes in ApoB) rather than by LDL cholesterol. This is sup- Statin use has been associated with an increase in risk of T2DM, and Mendelian randomization studies have reported an association between PCSK9 loss-of-function mutations and risk of diabetes 30, 32, 33 ; however, we did not see any clinically relevant effect of alirocumab on change in glycaemic variables or in use of antihyperglycaemic agents in the present study, supporting previous pooled analyses and sub-analyses, 22, 34, 35 and the more recent analysis from the FOURIER study, 11, 26 which indicated no meaningful effect of PCSK9 inhibitors on either HbA1c or FPG levels or on rates of newonset diabetes. However, larger study populations and longer-term studies are required to further validate the long-term effects of PCSK9 inhibition, as use of these therapies is likely to be lifelong.
In this study, alirocumab was generally well tolerated, with comparable rates of TEAEs between alirocumab and usual care. No local injection-site reactions (defined as those deemed to be allergic and requiring medical consultation) were reported in this study in either treatment arm.
The rate of persistent anti-drug antibodies observed in the present study was similar to the overall rate seen in a pooled analysis of 10 ODYSSEY studies, which demonstrated substantial LDL cholesterol reductions that were maintained over the course of studies, regardless of anti-drug antibody status. 36 Limitations of the present study include its relatively short duration and the number of individuals enrolled, which did not allow analysis of rare adverse events. The awareness of treatment might have introduced bias by study participants and investigators. 37 Simultaneous addition of UC therapies was not included in the protocol, although it is acknowledged that this may be recommended in real-life practice.
In conclusion, among individuals with T2DM and mixed dyslipidaemia whose total atherogenic cholesterol burden was inadequately controlled despite maximally tolerated statin therapy, increasing the clearance of atherogenic lipoproteins with a PCSK9 inhibitor more effectively reduced total atherogenic cholesterol levels compared with the usual lipid-lowering therapeutic approaches currently used. 
